Role of withdrawal in reinstatement of morphine-conditioned place preference.
BACKGROUND
Relapse is a major characteristic of drug addiction and the primary problem in treating drug abuse. Based on the negative reinforcement view of addiction, in which the motivation to take drugs is thought to result from the desire to avoid the aversive effect of drug withdrawal, it has been theorized that withdrawal symptoms play a major role in the maintenance of and relapse to drug taking. However, the role of withdrawal in relapse has not yet been systemically investigated in the reinstatement model.


OBJECTIVE
Using a conditioned place preference (CPP) paradigm, we examined the role of different morphine withdrawal states (spontaneous withdrawal, naloxone-precipitated withdrawal, and conditioned withdrawal) in relapse to drug seeking.


METHODS
Rats alternately received morphine (10 mg/kg, s.c.) and saline for 8 days to acquire the CPP. The morphine CPP disappeared after a 2-week extinction phase of saline-paired training. Rats were then chronically administered morphine to induce physical dependence. The different withdrawal states were induced and their roles in the reinstatement of extinguished CPP were assessed. During conditioned withdrawal, trunk blood samples were taken and the corticosterone level was measured by radioimmunoassay. To examine the role of corticotropin-releasing factor (CRF) receptor antagonist on conditioned-withdrawal-induced reinstatement of CPP, different doses of alpha-helical CRF (0.1 and 1 mug, i.c.v.) were administered 30 min prior to the CPP testing.


RESULTS
The results show that morphine spontaneous withdrawal and naloxone-precipitated morphine withdrawal were ineffective in reinstatement morphine CPP. However, the withdrawal cues significantly elicited the reinstatement of CPP and increased corticosterone level. Moreover, pretreatment with the CRF receptor antagonist alpha-helical CRF (1 mug, i.c.v.) significantly attenuated the effects of withdrawal cues on reinstatement of CPP and corticosterone levels.


CONCLUSIONS
These findings demonstrate that the cues associated with previous drug withdrawal play a major role in drug relapse and that activation of the CRF receptor is involved in conditioned-withdrawal-induced reinstatement. The present study suggests that CRF receptor antagonists might be of value in the treatment and prevention of relapse to drug seeking after long-term abstinence.
Lu
Lin
L
National Laboratory of Medical Neurobiology and Pharmacology Research Center, Fudan University, 138 Yi Xue Yuan Road, Shanghai 200032, China.
Chen
Hai
H
Su
Wenjuan
W
Ge
Xin
X
Yue
Wen
W
Su
Fen
F
Ma
Lan
L
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D003213:Conditioning, Psychological / Q000187:drug effects*; D003346:Corticotropin-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D007276:Injections, Intraventricular; D007279:Injections, Subcutaneous; D008297:Male; D009020:Morphine / Q000008:administration & dosage / Q000494:pharmacology*; D009021:Morphine Dependence / Q000503:physiopathology*; D009270:Naloxone / Q000008:administration & dosage / Q000494:pharmacology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology; D011863:Radioimmunoassay / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000502:physiology; D012054:Reinforcement, Psychology; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*
D006727:Hormone Antagonists; D010446:Peptide Fragments; D018019:Receptors, Corticotropin-Releasing Hormone; D009270:Naloxone; D009020:Morphine; D003346:Corticotropin-Releasing Hormone; C045089:corticotropin releasing hormone (9-41)
Psychopharmacology (Berl). 1989;97(1):59-64
2496428
Brain Res. 2002 Sep 20;950(1-2):1-9
12231223
J Psychiatry Neurosci. 2000 Mar;25(2):125-36
10740986
Prog Neurobiol. 1998 Dec;56(6):613-72
9871940
Neurosci Biobehav Rev. 2003 Aug;27(5):457-91
14505687
Psychopharmacology (Berl). 2000 Dec;153(1):31-43
11255927
Fed Proc. 1985 Jan;44(1 Pt 2):259-63
3871412
Nat Rev Neurosci. 2001 Feb;2(2):119-28
11252991
Psychopharmacology (Berl). 2003 Jul;168(1-2):3-20
12402102
Science. 1997 Oct 3;278(5335):66-70
9311929
N Engl J Med. 1988 May 5;318(18):1173-82
3283549
Psychol Rev. 1974 Mar;81(2):119-45
4817611
Nature. 2000 Jun 29;405(6790):1013-4
10890431
Brain Res Brain Res Rev. 1997 Dec;25(3):359-72
9495563
Behav Brain Res. 2000 Oct;115(1):39-47
10996406
Behav Brain Res. 2002 Nov 15;136(2):389-97
12429400
Br J Addict. 1992 Aug;87(8):1133-44
1511227
Pharmacol Rev. 2002 Mar;54(1):1-42
11870259
J Neurochem. 2000 Jan;74(1):199-208
10617121
Science. 1981 Sep 18;213(4514):1394-7
6267699
Pharmacol Rev. 2001 Jun;53(2):209-43
11356984
Annu Rev Pharmacol Toxicol. 1996;36:359-78
8725394
Neuroreport. 2000 Aug 3;11(11):2373-8
10943688
Psychopharmacology (Berl). 1999 Jul;145(1):21-30
10445369
Psychol Rev. 1984 Apr;91(2):251-68
6571424
Neuropsychopharmacology. 1996 Nov;15(5):497-505
8914123
Eur J Neurosci. 2000 Dec;12(12):4398-404
11122350
Psychopharmacology (Berl). 1995 Jun;119(3):334-41
7675970
Br J Pharmacol. 1996 Sep;119(1):174-82
8872371
Neuropsychopharmacology. 2003 May;28(5):865-71
12736632
Brain Res. 1995 Mar 27;675(1-2):89-97
7796157
Eur J Pharmacol. 2001 Dec 7;432(2-3):153-61
11740951
Drug Alcohol Depend. 1998 Jun-Jul;51(1-2):23-47
9716928
Neuroscience. 2003;119(2):497-505
12770563
Psychopharmacology (Berl). 2000 Oct;152(2):140-8
11057517
Pavlov J Biol Sci. 1979 Jul-Sep;14(3):170-6
45498
Brain Res Brain Res Rev. 2000 Aug;33(1):13-33
10967352
Ann N Y Acad Sci. 1999;897:27-45
10676433
Brain Res Mol Brain Res. 1998 Apr;55(2):221-31
9582424
Psychopharmacologia. 1976;46(1):19-25
1257363
Brain Res. 1988 Dec 6;474(2):364-8
2463060
Am J Psychiatry. 1999 Jan;156(1):11-8
9892292
Science. 1997 Oct 3;278(5335):52-8
9311926
Ann N Y Acad Sci. 1994 Oct 31;739:176-84
7832471
Psychopharmacology (Berl). 2002 Jan;159(2):125-32
11862339
Psychiatr Clin North Am. 1986 Sep;9(3):413-25
3534813
Neurosci Lett. 2000 Sep 22;291(3):191-5
10984639
Psychopharmacology (Berl). 1983;79(1):29-31
6403961
Am J Addict. 2001;10 Suppl:3-15
11268820
Am J Psychiatry. 1948 Nov;105(5):329-38
18890902
J Neurosci. 1996 Mar 1;16(5):1957-63
8774462
Brain Res. 2001 Jul 20;908(1):86-92
11457434
Psychoneuroendocrinology. 1997 May;22(4):237-59
9226728
Brain Res Bull. 1989 Oct-Nov;23(4-5):373-87
2556210
Pharmacol Biochem Behav. 2002 Mar;71(3):517-29
11830186
Nat Neurosci. 2001 Sep;4(9):943-7
11528427
J Pharmacol Exp Ther. 2002 Jun;301(3):785-9
12023504
Ann N Y Acad Sci. 1992 Jun 28;654:400-15
1632593
Am J Psychiatry. 1991 Dec;148(12):1712-6
1957935
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):12040-5
8876259
Neurosci Biobehav Rev. 1995 Spring;19(1):39-51
7770196
Neurosci Biobehav Rev. 1989 Summer-Fall;13(2-3):135-40
2682399
Psychopharmacologia. 1967;10(3):255-84
5626647
Neuropharmacology. 2004;47 Suppl 1:167-79
15464135
J Neurochem. 2003 Jun;85(6):1604-13
12787079
Neuropharmacology. 1992 Dec;31(12):1231-41
1335131
Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91
8401595
J Abnorm Psychol. 1988 May;97(2):118-32
3290303